Takasaki, Akihiro
Kurita, Tairo http://orcid.org/0000-0002-2882-6512
Hirabayashi, Yosuke
Matsuo, Hiroshi
Tanoue, Akiko
Masuda, Jun
Yamanaka, Takashi
Katayama, Kan
Machida, Hirofumi
Ichikawa, Takehiko
Ito, Masaaki
Dohi, Kaoru
Clinical trials referenced in this document:
Documents that mention this clinical trial
Prognosis of acute myocardial infarction in patients on hemodialysis stratified by Killip classification in the modern interventional era (focus on the prognosis of Killip class 1)
https://doi.org/10.1007/s00380-021-01919-7
Documents that mention this clinical trial
Prognosis of acute myocardial infarction in patients on hemodialysis stratified by Killip classification in the modern interventional era (focus on the prognosis of Killip class 1)
https://doi.org/10.1007/s00380-021-01919-7
Article History
Received: 19 February 2021
Accepted: 28 July 2021
First Online: 4 August 2021
Declarations
:
: Kaoru Dohi received lecture fees equal to or more than 1000,000 yen from Otsuka Pharma Inc. and departmental research grant support equal to or more than 1,000,000 yen from Otsuka Pharmaceutical Co., Ltd.in 2020. Kaoru Dohi received lecture fee equal to or more than 1,000,000 yen from Otsuka Pharmaceutical Co., Ltd in 2019. Kaoru Dohi received lecture fee equal to or more than 500,000 yen from Otsuka Pharmaceutical Co., Ltd and Takeda Pharmaceutical Company Limited in 2018. Masaki Ito received departmental research grant support equal to or more than 1,000,000 yen from Otsuka Pharmaceutical Co., Ltd. in 2019. Masaki Ito received lecture fees equal to or more than 500,000 yen from Daiichi Sankyo Co., Ltd. in 2019. Masaaki Ito received departmental research grant support equal to or more than 1,000,000 yen from Otsuka Pharma Inc. and Daiichi, Sankyo Company Limited in 2018. Takasaki Akihiro, Tairo Kurita, Yosuke Hirabayashi, Hiroshi Matsuo, Akiko Tanoue, Jun Masuda, Takashi Yamanaka, Kan Katayama, Hirofumi Machida, and Takehiko Ichikawa have no financial conflicts of interest to disclose concerning this study.